Actelion Ltd. | Ownership
Companies that own Actelion Ltd.
Norges Bank Investment Management
3,222,066
3%
-110,984
0.13%
04/27/2017
The Vanguard Group, Inc.
407,245
0.38%
969
0%
10/31/2017
APG Asset Management NV
345,178
0.32%
345,178
0.06%
12/31/2016
Canada Pension Plan Investment Board
264,000
0.25%
26,000
0.07%
03/31/2017
SEB Investment Management AB
245,761
0.23%
-16,779
0.2%
12/31/2016
UBS Asset Management (UK) Ltd.
201,772
0.19%
201,772
0.07%
11/30/2016
UBP-Gestion Institutionnelle SA
182,132
0.17%
182,132
2.8%
12/31/2016
BC Investment Management Corp.
179,585
0.17%
-3,764
0.13%
03/31/2016
P. Schoenfeld Asset Management LP (New York)
142,174
0.13%
142,174
2.97%
01/31/2017
State of Wisconsin Investment Board
139,546
0.13%
50,302
0.07%
12/31/2016
| Address |
Gewerbestrasse 16
Allschwil Basel-Landschaft (Basle Country) 4123
Switzerland
|
|
Employees
|
- |
| Website |
http://www.actelion.com |
| Updated |
07/08/2019 |
| Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs. It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs. Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. |
